Authors: Walenga, JM Hoppensteadt, D Pifarre, R Fox, NL Forman, S Hunninghake, DB Campeau, L Herd, JA Hoogwerf, BJ Hickey, A Probstfield, JL Terrin, ML

Citation: Jm. Walenga et al., The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment, J THROMB TH, 11(2), 2001, pp. 143-149

Authors: Probstfield, JL Applegate, WB Berge, KE Cutler, JA Davis, B Furberg, CD Hawkins, CM Pressel, S Schron, EB Smith, WM

Citation: Jl. Probstfield et al., Systolic Hypertension in the Elderly Program (SHEP): The first demonstration that lowering systolic hypertension reduced total stroke and all coronary heart disease, CLINICAL TRIALS IN HYPERTENSION, 2001, pp. 195-231

Authors: Perry, HM Davis, BR Price, TR Applegate, WB Fields, WS Guralnik, JM Kuller, L Pressel, S Stamler, J Probstfield, JL

Citation: Hm. Perry et al., Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke - The Systolic Hypertension in the Elderly Program (SHEP), J AM MED A, 284(4), 2000, pp. 465-471

Authors: Walenga, JM Hoppensteadt, D Pifarre, R Cressman, MD Hunninghake, DB Fox, NL Terrin, ML Probstfield, JL

Citation: Jm. Walenga et al., Hemostatic effects of 1 mg daily warfarin on post CABG patients, J THROMB TH, 7(3), 1999, pp. 313-318

Authors: Cosgrove, N Borhani, NO Bailey, G Borhani, P Levin, J Hoffmeier, M Krieger, S Lovato, LC Petrovitch, H Vogt, T Wilson, AC Breeson, V Probstfield, JL

Citation: N. Cosgrove et al., Mass mailing and staff experience in a total recruitment program for a clinical trial: The SHEP experience, CONTR CL TR, 20(2), 1999, pp. 133-148